Tilsner V, Greul W
MMW Munch Med Wochenschr. 1975 May 16;117(20):865-8.
Compared with streptokinase, thrombolytic treatment with urokinase has the advantages of being better tolerated and of practically unlimited applicability. Its disadvantage is the high cost. A good lytic action can be obtained with a dosage of 150,000 Ploug Units/12 hours for a duration of lysis of 8-14 days combined with heparin, the therapy being monitored by determination of the products of fibrinolysis. This dosage is not possible if the time factor plays a decisive role in the success of the treatment, e.g. in myocardial infarction. Urokinase is indicated when streptokinase cannot be used, or if continuation of the streptokinase therapy is necessary because of extensive thromboses.
与链激酶相比，尿激酶溶栓治疗具有耐受性更好和实际应用范围几乎不受限的优点。其缺点是成本高昂。给予150,000普洛单位/12小时的剂量，持续溶栓8 - 14天，并联合肝素治疗，通过测定纤维蛋白溶解产物进行监测，可获得良好的溶栓效果。如果时间因素对治疗成功起决定性作用，例如在心肌梗死中，这种剂量是不可行的。当不能使用链激酶，或者由于广泛血栓形成而需要继续链激酶治疗时，可使用尿激酶。
